Hadean Ventures

Hadean Ventures is a European life science venture capital firm headquartered in Oslo, Norway, with an additional office in Stockholm, Sweden. They focus on investing in life science startups across Europe, particularly in the Nordics and German-speaking countries. The firm manages approximately EUR 230 million in assets through its two main funds, Hadean Capital I and Hadean Capital II, which collectively exceed their initial targets due to strong investor support. The firm's investment strategy spans across pharmaceuticals, biotech, medtech, diagnostics, and digital health, targeting early to mid-stage companies with the potential to address unmet medical needs. Notable investments include Alex Therapeutics, Arthex Biotech, Complement Therapeutics, Emergence Therapeutics, Ribbon Biolabs, and TargED. Their first successful exit was the acquisition of Emergence Therapeutics by Eli Lilly in 2023. Hadean Ventures is led by Managing Partners Ingrid Teigland Akay and Walter Stockinger, who bring extensive experience in life sciences and venture capital. The team is recognized for its hands-on operational management and strategic guidance, fostering significant advancements in the healthcare sector. For startups seeking investment from Hadean Ventures, it is advantageous to demonstrate strong innovation in addressing critical healthcare challenges and to align with their focus on transformative life science solutions​.